Actuate Therapeutics presents Phase 2 elraglusib data showing overall survival benefit in pancreatic cancer

ACTUATE THERAPEUTICS, INC.

Phase 2 (Actuate-1801 Part 3B) data of elraglusib with gemcitabine/nab-paclitaxel showed overall survival benefit in first-line metastatic pancreatic cancer.
KOL event featured four GI oncology experts who discussed elraglusib's mechanism targeting EMT, NF-kB, and immune activation.
Dr. Colin Weekes stated elraglusib is the first drug in years to improve outcomes on standard chemotherapy backbones.
Drug was well-tolerated; neutropenia occurred but no febrile neutropenia; transient vision changes resolved within 24 hours.
Study PI Dr. Deva Mahalingam highlighted unique GSK-3 beta inhibition and survival curve separation in a challenging patient population.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.